Lakefront Biotherapeutics (GLPGF) Cash from Operations (2015 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Cash from Operations for 12 consecutive years, with -$96.9 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Cash from Operations fell 138.56% year-over-year to -$96.9 million in Q1 2026; TTM through Mar 2026 was -$256.2 million, a 61.98% increase from a year earlier, with the FY2025 full-year figure at -$290.9 million, up 16.02% from the prior year.
• Cash from Operations was -$96.9 million for Q1 2026 at Lakefront Biotherapeutics, down from -$55.2 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$40.6 million in Q1 2025 and troughed at -$510.7 million in Q4 2022.
• A 5-year average of -$167.6 million and a median of -$96.9 million in 2026 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations surged 85.48% in 2024 and plunged 138.56% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at -$510.7 million in 2022, then increased by 14.47% to -$436.8 million in 2023, then surged by 85.48% to -$63.4 million in 2024, then climbed by 12.92% to -$55.2 million in 2025, then plunged by 75.36% to -$96.9 million in 2026.
• The last three Cash from Operations figures came in at -$96.9 million (Q1 2026), -$55.2 million (Q4 2025), and -$40.6 million (Q1 2025), per Business Quant data.